Merck Purchase Tilos Therapeutics for $773 million

If you work in Tech Transfer,  there is no doubt that every day is varied; involving discussions around new or existing technologies, analysis of new inventions (including market analysis and prior art searching), working with patent attorneys to coordinate new patent filings or existing patent management, project development and so much more.

But nothing is as fulfilling as when a Tech Transfer specialist, in this case, Dublin born Colm Lawler Senior Licensing Manager of Partners Group learns of the recent acquisition of start-up company Tilos, by global giant Merck for $773m .  Colm helped Tilos get off the ground back in 2016. This technology was created in Brigham and Women’s Hospital, licensed to Tilos Therapeutics, and now acquired by Merck . A great example of successful technology transfer. Colm has commented that this is definitely one of the most satisfying projects of his career and he is excited to see what Tilos can do in the years ahead. Huge congratulations Colm and all at Partners and of course to Tilos Therapeutics Read the press release in full here.

About the author

Back to Insights